Loading company…
Pacira develops and sells non-opioid therapies for pain management, including postsurgical and osteoarthritis-related treatments.
Pacira Pharmaceuticals develops non-opioid pain management therapies, including EXPAREL®, iovera°, and ZILRETTA®. Its products address postsurgical pain and osteoarthritis-related knee pain, and are marketed to healthcare providers in the United States. Pacira went public in February 2011, raising USD 42 mn through the sale of 6 million shares at USD 7 per share. In fiscal year 2024, it reported revenue of USD 697.19 mn and EBITDA of USD 5.41 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in